The pneumococcal alpha-glycerophosphate oxidase enhances nasopharyngeal colonization through binding to host glycoconjugates

Simple item page
dc.contributor.authorMahdi, L.
dc.contributor.authorHiggins, M.
dc.contributor.authorDay, C.
dc.contributor.authorTiralongo, J.
dc.contributor.authorHartley-Tassell, L.
dc.contributor.authorJennings, M.
dc.contributor.authorGordon, D.
dc.contributor.authorPaton, A.
dc.contributor.authorPaton, J.
dc.contributor.authorOgunniyi, A.
dc.date.issued2017
dc.description.abstractStreptococcus pneumoniae (the pneumococcus) is a major human pathogen, causing a broad spectrum of diseases including otitis media, pneumonia, bacteraemia and meningitis. Here we examined the role of a potential pneumococcal meningitis vaccine antigen, alpha-glycerophosphate oxidase (SpGlpO), in nasopharyngeal colonization. We found that serotype 4 and serotype 6A strains deficient in SpGlpO have significantly reduced capacity to colonize the nasopharynx of mice, and were significantly defective in adherence to human nasopharyngeal carcinoma cells in vitro. We also demonstrate that intranasal immunization with recombinant SpGlpO significantly protects mice against subsequent nasal colonization by wild type serotype 4 and serotype 6A strains. Furthermore, we show that SpGlpO binds strongly to lacto/neolacto/ganglio host glycan structures containing the GlcNAcβ1-3Galβ disaccharide, suggesting that SpGlpO enhances colonization of the nasopharynx through its binding to host glycoconjugates. We propose that SpGlpO is a promising vaccine candidate against pneumococcal carriage, and warrants inclusion in a multi-component protein vaccine formulation that can provide robust, serotype-independent protection against all forms of pneumococcal disease.
dc.description.statementofresponsibilityLayla K. Mahdi, Melanie A. Higgins, Christopher J. Day, Joe Tiralongo, Lauren E. Hartley-Tassell, Michael P. Jennings, David L. Gordon, Adrienne W. Paton, James C. Paton, Abiodun D. Ogunniyi
dc.identifier.citationEBioMedicine, 2017; 18:236-243
dc.identifier.doi10.1016/j.ebiom.2017.03.002
dc.identifier.issn2352-3964
dc.identifier.issn2352-3964
dc.identifier.orcidMahdi, L. [0000-0002-5878-8385]
dc.identifier.orcidPaton, J. [0000-0001-9807-5278]
dc.identifier.orcidOgunniyi, A. [0000-0001-9308-5629]
dc.identifier.urihttp://hdl.handle.net/2440/109089
dc.language.isoen
dc.publisherElsevier
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/565526
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1071659
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/627142
dc.rights© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.source.urihttps://doi.org/10.1016/j.ebiom.2017.03.002
dc.subjectBacterial pathogens; Streptococcus pneumonia; protein vaccines; Pneumococcal disease; colonization; adherence; host glycoconjugates; alpha-glycerophosphate oxidase; immunization
dc.titleThe pneumococcal alpha-glycerophosphate oxidase enhances nasopharyngeal colonization through binding to host glycoconjugates
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_109089.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download

Collections

Molecular and Biomedical Science publications